Not yet recruiting
Gene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical Study
NCT07939295· Phase 1/2· Kanglin Biotechnology (Hangzhou) Co., Ltd.· Source
Contact: Jun Liu, Professor, Chief Physician, MD, Ph D
Not yet recruiting
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Qing Xie, doctor
Not yet recruiting
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
NCT07923396· Phase 1· Ruijin Hospital· Source
Contact: Jun Zhang
Recruiting
Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
NCT07323095· Phase 2· Atom Therapeutics Co., Ltd· Source
Contact: Renbo Gao
Recruiting
Directional PSA Versus STN DBS for TD-PD
NCT07700862· Ruijin Hospital· Source
Contact: Dianyou Li, MD, PhD
Recruiting
A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer
NCT07649928· Early phase 1· Ruijin Hospital· Source
Contact: Chenlei Wen
Recruiting
BCI With 40Hz Stimulation in Alzheimer's Disease
NCT07618481· Ruijin Hospital· Source
Contact: Chao Gao
Not yet recruiting
A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies
NCT07532746· Phase 1· Kousai Bio Co., Ltd.· Source
Contact: Weili Zhao
Active, not recruiting
A Study of CS060380 Tablets in Patients With MASH and Obesity
NCT07466017· Phase 2· Cascade Pharmaceuticals, Inc· Source
Enrolling by invitation
Study on the Correlation Between Plasma Orexin Levels During the Recovery Period and Emergence Delirium in Elderly Patients
NCT07726875· Ruijin Hospital· Source
Recruiting
A Study of SHR-2173 in Participants With Primary IgA Nephropathy
NCT07354932· Phase 2· Guangdong Hengrui Pharmaceutical Co., Ltd· Source
Contact: Jingyuan Xie (principal investigator)
Not yet recruiting
A Study of Cizutamig for Patients With Ulcerative Colitis
NCT07353450· Early phase 1· Ruijin Hospital· Source
Contact: Zu yan He
Not yet recruiting
Clinical Study on the Safety and Efficacy of a New Magnetic Navigation Radiofrequency Ablation Catheter for Rapid Arrhythmia
NCT07067372· Shanghai MicroPort EP MedTech Co., Ltd.· Source
Contact: Qi NA Jin
Recruiting
A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease
NCT07195825· Phase 1· Shanghai Xinzhi BioMed Co., Ltd.· Source
Contact: Jun Liu, MD
Recruiting
A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure
NCT07265349· Phase 1/2· Tasly Pharmaceutical Group Co., Ltd· Source
Contact: Qiang Zhao
Recruiting
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07294625· Early phase 1· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Jianqing Mi
Recruiting
Safety and Efficacy Evaluation of Cryoablation in the Treatment of Ground-Glass Nodules
NCT07232433· Ruijin Hospital· Source
Contact: Hecheng Li
Recruiting
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
NCT07168161· Phase 3· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source
Contact: Jingyuan Xie
Enrolling by invitation
Efficacy and Safety of Temporal Interference Stimulation on Cognitive Function in Patients With Early-Stage Alzheimer's Disease
NCT07543094· Ruijin Hospital· Source
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437· Phase 2/3· Pfizer· Source
Recruiting
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
NCT07272499· Phase 2· Ruijin Hospital· Source
Contact: Weili Zhao M.D. and Ph.D
Not yet recruiting
Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT07122609· Phase 2· Ruijin Hospital· Source
Contact: Weili Zhao, Professor
Recruiting
Predicting DBS Outcomes in Dystonia Using Wearable Gait Sensors
NCT07323602· Ruijin Hospital· Source
Contact: Li
Recruiting
CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
NCT07022964· Phase 1/2· Beijing GoBroad Hospital· Source
Contact: Haiyang LU, Ph.D
Recruiting
XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia
NCT06980155· Early phase 1· Shanghai Jiao Tong University School of Medicine· Source
Contact: Junmin Li
Recruiting
Comparison of Drainage Methods in Minimally Invasive Esophagectomy (DEMURE)
NCT07004634· Ruijin Hospital· Source
Contact: Dingpei Han, PhD, MD
Recruiting
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
NCT06925464· Phase 1/2· Beijing GoBroad Hospital· Source
Contact: Haiyang LU, Ph.D
Recruiting
REGEND001 Autologous Basal Layer Stem Cell Transplantation for Chronic Obstructive Pulmonary Disease (COPD): A Translational Application Study
NCT06946953· Phase 1/2· Ruijin Hospital· Source
Contact: Jiayang Yan, Ph.D
Recruiting
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer
NCT07035002· Phase 1· Ruijin Hospital· Source
Contact: Ren Zhao, M.D., Ph.D.
Not yet recruiting
Cognitive Impairment Cohort Study of the Elderly Population in YuGarden
NCT06325527· Ruijin Hospital· Source
Contact: Jinwen Xiao
Recruiting
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
NCT06221748· Phase 2/3· RemeGen Co., Ltd.· Source
Contact: Jun Zhang, M.D
Active, not recruiting
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841· Phase 2· Shanghai Ming Ju Biotechnology Co., Ltd.· Source
Active, not recruiting
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
NCT05479708· BAIYONG SHEN· Source
Recruiting
SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer
NCT05576480· Phase 2· Ruijin Hospital· Source
Contact: Ren Zhao, M.D., Ph.D.
Recruiting
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in PANCEATIC Cancer (ASCEND-PANCREATIC)
NCT05556603· Ruijin Hospital· Source
Contact: Qian Zhan, MD
Recruiting
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
NCT05365581· Phase 1· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development, Inc.
Active, not recruiting
Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy
NCT04513418· Phase 3· Hecheng Li M.D., Ph.D· Source
Active, not recruiting
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
NCT04285086· Phase 3· PharmaEssentia· Source
Recruiting
Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia
NCT06534658· Ruijin Hospital· Source
Contact: Jintao Wang